Blood
Articles in this Issue
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: A multi-center study in China
Abstract Background In 2022, the World Health Organization (WHO) and the International Consensus Classification of Myeloid and Lymphoma ( IC...
Epidemiological characteristics of myeloproliferative neoplasms in Brazil: A multicenter retrospective study
Abstract Context: Philadelphia-negative myeloproliferative neoplasms (Ph- MPNs), including polycythemia vera (PV), essential thrombocythemia...
Discovery of JNJ-87562761, a novel anti-GPRC5D enhanced effector function (eEF) antibody with multiple mechanisms of action for the treatment of multiple myeloma
Abstract Background: Antibody and cellular therapies have reshaped the multiple myeloma (MM) therapeutic landscape in recent years resulting...
Unmasking myeloid sarcoma: A SEER database study of an underrecognized malignancy
Abstract Introduction: The classification of “myeloid sarcoma” (MS) is often considered imprecise and misleading. A more accurate term is ext...
Can we perform allogeneic hematopoietic cell transplantation (HCT) safely in patients with limited social supports and substantial psychosocial complexity?
Abstract Introduction Allogeneic HCT is a potentially curative therapy for hematologic disorders. Despite its clinical benefits, disparities...
Defining functional high-risk multiple myeloma in the era of modern induction therapy
Abstract Background: Treatment of multiple myeloma (MM) has advanced dramatically over the past decade with median overall survival (OS) for...
Dysbiosis of the gut microbiota induces brain inflammation in neonatal necrotizing enterocolitis via the gut-brain axis
Abstract Background Necrotizing enterocolitis (NEC) is the most common fatal gastrointestinal emergency in premature infants. The intestinal...
Safety evaluation for less restrictive discharge criteria for patients receiving high dose methotrexate
Abstract Introduction: High Dose Methotrexate (HD MTX) is commonly given either as a single agent or in combination to treat patients with v...
30 years of classical hematology drugs in the US: Approvals, costs, and sales
Abstract Background: In 2022, Medicare alone spent $42.1 billion on prescription drugs, with antineoplastic and classical hematology drugs a...
Normal B Cells in MBL follow divergent maturation pathways that correlate with the IGHV mutation status of the pre-leukemic clone
Abstract CLL and its precursor, monoclonal B-cell lymphocytosis (MBL), are associated with immune deficits. In MBL, the higher percentages o...
Phase I study of a CD19-directed CAR-T cell therapy for Relapsed/refractory mantle cell lymphomas(MCL)
Abstract Abstract Here we presented the safety and efficacy of a novel CD19 CAR-T, named IM19, in relapsed/refractory mantle cell lymphoma (...
United Arab Emirates first population-based acute leukemia registry
Abstract Compared to Western registries, limited data exist on acute leukemia in rapidly developing Middle Eastern nations with diverse expa...
Characteristics at diagnosis of autoimmune hemolytic anemias in adults: First results from a prospective, multicenter cohort of 413 patients included in the carmen-France registry
Abstract Autoimmune hemolytic anemias (AIHA) encompass with three main different subtypes based on the properties of the autoantibody: warm...
Virtual reality and hypnosis to alleviate anxiety and pain in patients undergoing bone marrow aspiration and biopsy: A randomized controlled trial
Abstract Background: Bone marrow aspiration and biopsy (BMAB) is an essential diagnostic procedure in hematology. Despite standard pharmacol...
First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients
Abstract Introduction. The outcome of adult Ph+ ALL has improved with the introduction of tyrosine kinase inhibitors (TKI) and, more recentl...
Poor survival and younger age in patients with blast Phase chronic myeloid leukemia in a developing country: A multicenter real-world study of 138 patients.
Abstract Background: Chronic myeloid leukemia (CML) in blast phase (BP) remains a very difficult condition to treat despite current therapie...
A first-in-human phase 1 Study of cbx-250, a TCR-mimetic bispecific T cell engager targeting CG1/ HLA-a*02:01 in patients with relapsed or refractory AML, HR-MDS, or CMML (CROSSCHECK-001) (Trial in Progress)
Abstract Background & Significance: Significant unmet medical needs exist in the treatment of acute myeloid leukemia (AML), higher risk m...
Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts
Abstract Introduction The International Prognostic Index (IPI) is widely used to stratify risk in large B-cell lymphoma (LBCL) across all ag...
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial
Abstract Backgroud: Relapsed or refractory (R/R) indolent non-Hodgkin lymphomas (iNHLs) are incurable diseases. Based on the ZUMA-5 study, a...
Impact of essential thrombocythemia on in-hospital outcomes and thrombotic complications in patients hospitalized with COVID-19: A national inpatient sample analysis (2016–2022)
Abstract Background: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by elevated platelet counts and a...
Longterm survival and late effects following hematopoietic cell transplantation for sickle cell disease into a modern era: A center for international blood and marrow transplant research (CIBMTR) analysis
Abstract Survival following curative hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) is excellent using matched relat...
Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study
Abstract Introduction: Multiple myeloma (MM) accounts for nearly 20% of all hematologic cancers in the US and remains a substantial clinical...
Clinical activity and immune correlates of glofitamab combined with tislelizumab in relapsed/refractory follicular lymphoma: A translational study
Abstract Background Patients with relapsed/refractory follicular lymphoma (R/R FL) refractory to anti-CD20 therapy face dismal outcomes and l...
Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial
Abstract Introduction:Lenalidomide (LEN) plus daratumumab (DARA) and dexamethasone (DEX) is a standard-of-care treatment for transplant-inel...
Bone marrow microenvironment overlap between vexas and myelodysplastic syndrome demonstrated by targeted transcriptomic and artificial intelligence
Abstract Introduction: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an inflammatory process that involves bo...